BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33889297)

  • 41. Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research Experience.
    Lier A; Penzel R; Heining C; Horak P; Fröhlich M; Uhrig S; Budczies J; Kirchner M; Volckmar AL; Hutter B; Kreutzfeldt S; Endris V; Richter D; Wolf S; Pfütze K; Neumann O; Buchhalter I; Morais de Oliveira CM; Singer S; Leichsenring J; Herpel E; Klauschen F; Jost PJ; Metzeler KH; Schulze-Osthoff K; Kopp HG; Kindler T; Rieke DT; Lamping M; Brandts C; Falkenhorst J; Bauer S; Schröck E; Folprecht G; Boerries M; von Bubnoff N; Weichert W; Brors B; Lichter P; von Kalle C; Schirmacher P; Glimm H; Fröhling S; Stenzinger A
    JCO Precis Oncol; 2018 Nov; 2():1-13. PubMed ID: 35135162
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tumor Mutational Burden From Tumor-Only Sequencing Compared With Germline Subtraction From Paired Tumor and Normal Specimens.
    Parikh K; Huether R; White K; Hoskinson D; Beaubier N; Dong H; Adjei AA; Mansfield AS
    JAMA Netw Open; 2020 Feb; 3(2):e200202. PubMed ID: 32108894
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identifying a wide range of actionable variants using capture-based ultra-deep targeted sequencing in treatment-naive patients with primary lung adenocarcinoma.
    Chen L; Chen M; Lin J; Chen X; Yu X; Chen Z; Jin L
    Int J Clin Exp Pathol; 2020; 13(3):525-535. PubMed ID: 32269691
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Using circulating cell-free DNA to monitor personalized cancer therapy.
    Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD
    Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Precision Medicine in Children and Young Adults with Hematologic Malignancies and Blood Disorders: The Columbia University Experience.
    Marks LJ; Oberg JA; Pendrick D; Sireci AN; Glasser C; Coval C; Zylber RJ; Chung WK; Pang J; Turk AT; Hsiao SJ; Mansukhani MM; Glade Bender JL; Kung AL; Sulis ML
    Front Pediatr; 2017; 5():265. PubMed ID: 29312904
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67,000 Patient Samples.
    Trabucco SE; Gowen K; Maund SL; Sanford E; Fabrizio DA; Hall MJ; Yakirevich E; Gregg JP; Stephens PJ; Frampton GM; Hegde PS; Miller VA; Ross JS; Hartmaier RJ; Huang SA; Sun JX
    J Mol Diagn; 2019 Nov; 21(6):1053-1066. PubMed ID: 31445211
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing.
    Cai H; Jing C; Chang X; Ding D; Han T; Yang J; Lu Z; Hu X; Liu Z; Wang J; Shang L; Wu S; Meng P; Lin L; Zhao J; Nie M; Yin K
    J Transl Med; 2019 Jun; 17(1):189. PubMed ID: 31164161
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.
    Hovelson DH; McDaniel AS; Cani AK; Johnson B; Rhodes K; Williams PD; Bandla S; Bien G; Choppa P; Hyland F; Gottimukkala R; Liu G; Manivannan M; Schageman J; Ballesteros-Villagrana E; Grasso CS; Quist MJ; Yadati V; Amin A; Siddiqui J; Betz BL; Knudsen KE; Cooney KA; Feng FY; Roh MH; Nelson PS; Liu CJ; Beer DG; Wyngaard P; Chinnaiyan AM; Sadis S; Rhodes DR; Tomlins SA
    Neoplasia; 2015 Apr; 17(4):385-99. PubMed ID: 25925381
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Variant call concordance between two laboratory-developed, solid tumor targeted genomic profiling assays using distinct workflows and sequencing instruments.
    Hampel KJ; de Abreu FB; Sidiropoulos N; Peterson JD; Tsongalis GJ
    Exp Mol Pathol; 2017 Apr; 102(2):215-218. PubMed ID: 28192086
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analytical and Clinical Validation of Expressed Variants and Fusions From the Whole Transcriptome of Thyroid FNA Samples.
    Angell TE; Wirth LJ; Cabanillas ME; Shindo ML; Cibas ES; Babiarz JE; Hao Y; Kim SY; Walsh PS; Huang J; Kloos RT; Kennedy GC; Waguespack SG
    Front Endocrinol (Lausanne); 2019; 10():612. PubMed ID: 31572297
    [No Abstract]   [Full Text] [Related]  

  • 51. Next-generation sequencing-based clinical sequencing: toward precision medicine in solid tumors.
    Wakai T; Prasoon P; Hirose Y; Shimada Y; Ichikawa H; Nagahashi M
    Int J Clin Oncol; 2019 Feb; 24(2):115-122. PubMed ID: 30515675
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comprehensive Genomic Profiling of High-Risk Pediatric Cancer Patients Has a Measurable Impact on Clinical Care.
    Summers RJ; Castellino SM; Porter CC; MacDonald TJ; Basu GD; Szelinger S; Bhasin MK; Cash T; Carter AB; Castellino RC; Fangusaro JR; Mitchell SG; Pauly MG; Pencheva B; Wechsler DS; Graham DK; Goldsmith KC
    JCO Precis Oncol; 2022 Apr; 6():e2100451. PubMed ID: 35544730
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine.
    Van Allen EM; Robinson D; Morrissey C; Pritchard C; Imamovic A; Carter S; Rosenberg M; McKenna A; Wu YM; Cao X; Chinnaiyan A; Garraway L; Nelson PS
    Oncotarget; 2016 Aug; 7(33):52888-52899. PubMed ID: 27167109
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients.
    Wang Y; Liu H; Hou Y; Zhou X; Liang L; Zhang Z; Shi H; Xu S; Hu P; Zheng Z; Liu R; Tang T; Ye F; Liang Z; Bu H
    Virchows Arch; 2018 Jun; 472(6):959-968. PubMed ID: 29705968
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Validation and implementation of a modular targeted capture assay for the detection of clinically significant molecular oncology alterations.
    Kuo AJ; Paulson VA; Hempelmann JA; Beightol M; Todhunter S; Colbert BG; Salipante SJ; Konnick EQ; Pritchard CC; Lockwood CM
    Pract Lab Med; 2020 Mar; 19():e00153. PubMed ID: 32123717
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures.
    Johnson A; Severson E; Gay L; Vergilio JA; Elvin J; Suh J; Daniel S; Covert M; Frampton GM; Hsu S; Lesser GJ; Stogner-Underwood K; Mott RT; Rush SZ; Stanke JJ; Dahiya S; Sun J; Reddy P; Chalmers ZR; Erlich R; Chudnovsky Y; Fabrizio D; Schrock AB; Ali S; Miller V; Stephens PJ; Ross J; Crawford JR; Ramkissoon SH
    Oncologist; 2017 Dec; 22(12):1478-1490. PubMed ID: 28912153
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.
    Cheng DT; Mitchell TN; Zehir A; Shah RH; Benayed R; Syed A; Chandramohan R; Liu ZY; Won HH; Scott SN; Brannon AR; O'Reilly C; Sadowska J; Casanova J; Yannes A; Hechtman JF; Yao J; Song W; Ross DS; Oultache A; Dogan S; Borsu L; Hameed M; Nafa K; Arcila ME; Ladanyi M; Berger MF
    J Mol Diagn; 2015 May; 17(3):251-64. PubMed ID: 25801821
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial.
    Lih CJ; Sims DJ; Harrington RD; Polley EC; Zhao Y; Mehaffey MG; Forbes TD; Das B; Walsh WD; Datta V; Harper KN; Bouk CH; Rubinstein LV; Simon RM; Conley BA; Chen AP; Kummar S; Doroshow JH; Williams PM
    J Mol Diagn; 2016 Jan; 18(1):51-67. PubMed ID: 26602013
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
    Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
    Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating
    Rich TA; Reckamp KL; Chae YK; Doebele RC; Iams WT; Oh M; Raymond VM; Lanman RB; Riess JW; Stinchcombe TE; Subbiah V; Trevarthen DR; Fairclough S; Yen J; Gautschi O
    Clin Cancer Res; 2019 Oct; 25(19):5832-5842. PubMed ID: 31300450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.